New Thinking Needed To Invigorate Japan Pharma Innovation
This article was originally published in PharmAsia News
If Japan is to invigorate pharma and biotech innovation there will need to be changes to ways of thinking by both investors and research-based ventures, along with closer co-ordination between academia, industry and the government, suggested participants in a panel discussion at the BioJapan meeting in Yokohama.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.